Verition Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-98,000
Closed -$559K – 2064
2026
Q2
$518K Buy
+98,000
New +$437K ﹤0.01% 1625
2025
Q2
– Sell
-35,805
Closed -$54.8K – 3609
2025
Q1
$54.8K Buy
+35,805
New +$76.4K ﹤0.01% 3193
2024
Q3
– Sell
-82,883
Closed -$91.2K – 3148
2024
Q2
$91.2K Buy
82,883
+29,048
+54% +$34.1K ﹤0.01% 2737
2024
Q1
$66.8K Buy
+53,835
New +$64.2K ﹤0.01% 2620
2023
Q4
– Sell
-299,685
Closed -$2.05M – 2294
2023
Q3
$2.05M Sell
299,685
-351,242
-54% -$3M 0.02% 782
2023
Q2
$6.75M Buy
650,927
+37,475
+6% +$339K 0.09% 296
2023
Q1
$4.96M Buy
613,452
+207,884
+51% +$2.64M 0.07% 370
2022
Q4
$6.39M Buy
405,568
+33,061
+9% +$532K 0.1% 249
2022
Q3
$5.86M Buy
372,507
+37,841
+11% +$596K 0.07% 362
2022
Q2
$4.67M Buy
334,666
+79,188
+31% +$1.11M 0.09% 285
2022
Q1
$4.4M Buy
255,478
+77,168
+43% +$1.05M 0.05% 451
2021
Q4
$2.59M Buy
+178,310
New +$2.7M 0.02% 706
2021
Q1
– Sell
-98,845
Closed -$640K – 1521
2020
Q4
$640K Buy
+98,845
New +$417K 0.01% 602
2020
Q3
– Sell
-65,000
Closed -$105K – 1030
2020
Q2
$105K Buy
+65,000
New +$87.1K ﹤0.01% 998

Other funds holding ACRS

Verition Fund Management's ACRS Position: Q3 2026 in Review

Verition Fund Management sold out of Aclaris Therapeutics (ACRS) in Q3 2026, closing a stake of 98,000 shares — an estimated $559K sold.

Verition Fund Management first reported a position in ACRS in Q2 2020 and held it in 14 quarters. The position peaked at $6.75M in Q2 2023. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Verition Fund Management reported no remaining Aclaris Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Verition Fund Management sold 98,000 Aclaris Therapeutics shares in Q3 2026, an estimated $559K.
  • Verition Fund Management first reported a position in Aclaris Therapeutics in Q2 2020 and held it in 14 quarters.
  • Verition Fund Management's Aclaris Therapeutics position peaked at $6.75M in Q2 2023.
  • 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.